{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:32:44Z","timestamp":1794619964007,"version":"4.9.1"},"reference-count":93,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,30]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Genetically modified T cells expressing chimeric antigen receptors (CARs) manufactured ex vivo have demonstrated high efficacy in patients with lymphoid hematologic malignancies, but their logistic complexity limits patient access. In vivo approaches generate the CAR-expressing T cells within the body but may have their own challenges. Recent clinical reports provide proof of concept for the feasibility and therapeutic potential of in vivo CAR gene delivery. We summarize clinical evidence and discuss the critical technical, biological, and safety considerations of this approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031898","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T19:55:02Z","timestamp":1779479702000},"page":"535-544","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Promises and potential pitfalls of in vivo CAR gene therapy"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2189-3579","authenticated-orcid":false,"given":"Dimitrios L.","family":"Wagner","sequence":"first","affiliation":[{"name":"1Center for Cell and Gene Therapy and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX"},{"name":"2Berlin Center for Advanced Therapies, Institute of Medical Immunology, and Berlin Institute of Health, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9574-3496","authenticated-orcid":false,"given":"Magdi","family":"Elsallab","sequence":"additional","affiliation":[{"name":"3Cellular Immunotherapy Program, Massachusetts General Hospital, Mass General Brigham Cancer Institute, Boston MA"},{"name":"4Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[{"name":"3Cellular Immunotherapy Program, Massachusetts General Hospital, Mass General Brigham Cancer Institute, Boston MA"},{"name":"4Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2026073011321590300_bib1","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"16","key":"2026073011321590300_bib2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"2026073011321590300_bib3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026073011321590300_bib4","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2026073011321590300_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"2026073011321590300_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"2026073011321590300_bib7","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"2026073011321590300_bib8","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"key":"2026073011321590300_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"43","key":"2026073011321590300_bib10","doi-asserted-by":"crossref","first-page":"e397912","DOI":"10.1200\/EDBK_397912","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"2026073011321590300_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"5","key":"2026073011321590300_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2026073011321590300_bib13","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","article-title":"Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms","volume":"30","author":"Michels","year":"2022","journal-title":"Mol Ther"},{"issue":"2","key":"2026073011321590300_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2026073011321590300_bib15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"issue":"10-11","key":"2026073011321590300_bib16","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41434-023-00390-5","article-title":"Successes and challenges in clinical gene therapy","volume":"30","author":"Kohn","year":"2023","journal-title":"Gene Ther"},{"issue":"15","key":"2026073011321590300_bib17","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"issue":"5","key":"2026073011321590300_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat Rev Genet"},{"issue":"5","key":"2026073011321590300_bib19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"46","key":"2026073011321590300_bib20","doi-asserted-by":"crossref","first-page":"17372","DOI":"10.1073\/pnas.0608138103","article-title":"Gene transfer in humans using a conditionally replicating lentiviral vector","volume":"103","author":"Levine","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026073011321590300_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/bs.mcb.2021.06.014","article-title":"Generation of CAR T-cells using \u03b3-retroviral vector","volume":"167","author":"Watanabe","year":"2022","journal-title":"Methods Cell Biol"},{"issue":"5259","key":"2026073011321590300_bib22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"issue":"18","key":"2026073011321590300_bib23","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.1214441110","article-title":"LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026073011321590300_bib24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s41467-018-03432-4","article-title":"Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein","volume":"9","author":"Nikolic","year":"2018","journal-title":"Nat Commun"},{"issue":"6220","key":"2026073011321590300_bib25","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"issue":"31","key":"2026073011321590300_bib26","doi-asserted-by":"crossref","first-page":"eabh2169","DOI":"10.1126\/sciadv.abh2169","article-title":"A single\u2013cell type transcriptomics map of human tissues","volume":"7","author":"Karlsson","year":"2021","journal-title":"Sci Adv"},{"issue":"1-2","key":"2026073011321590300_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.virusres.2013.06.003","article-title":"Understanding and altering cell tropism of vesicular stomatitis virus","volume":"176","author":"Hastie","year":"2013","journal-title":"Virus Res"},{"issue":"4","key":"2026073011321590300_bib28","doi-asserted-by":"crossref","first-page":"201065","DOI":"10.1016\/j.omton.2025.201065","article-title":"Optimization of the VSV-G backbone for amino terminal fusion with nanobodies allowing its specific retargeting to HER2 receptors","volume":"33","author":"Duqu\u00e9nois","year":"2025","journal-title":"Mol Ther Oncol"},{"issue":"1","key":"2026073011321590300_bib29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Sig Transduct Target Ther"},{"issue":"10","key":"2026073011321590300_bib30","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"16","key":"2026073011321590300_bib31","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026073011321590300_bib32","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol Ther"},{"issue":"6576","key":"2026073011321590300_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"11","key":"2026073011321590300_bib34","doi-asserted-by":"crossref","first-page":"e2304378","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"issue":"6753","key":"2026073011321590300_bib35","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"issue":"10500","key":"2026073011321590300_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"issue":"7","key":"2026073011321590300_bib37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1084\/jem.193.7.855","article-title":"CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis","volume":"193","author":"Oldenborg","year":"2001","journal-title":"J Exp Med"},{"issue":"493","key":"2026073011321590300_bib38","doi-asserted-by":"crossref","first-page":"eaav7325","DOI":"10.1126\/scitranslmed.aav7325","article-title":"Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates","volume":"11","author":"Milani","year":"2019","journal-title":"Sci Transl Med"},{"issue":"11","key":"2026073011321590300_bib39","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.15252\/emmm.201708148","article-title":"Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy","volume":"9","author":"Milani","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"4","key":"2026073011321590300_bib40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med Overseas Ed"},{"issue":"11","key":"2026073011321590300_bib41","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2026073011321590300_bib42","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","article-title":"In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study","volume":"32","author":"An","year":"2026","journal-title":"Nat Med"},{"issue":"suppl 2","key":"2026073011321590300_bib43","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood-2025-LBA-1","article-title":"Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti\u2013B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010 [abstract]","volume":"146","author":"Harrison","year":"2025","journal-title":"Blood"},{"issue":"15","key":"2026073011321590300_bib44","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In Vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"2026073011321590300_bib45","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp Mol Med"},{"issue":"16","key":"2026073011321590300_bib46","doi-asserted-by":"crossref","first-page":"eabf1333","DOI":"10.1126\/sciadv.abf1333","article-title":"A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells","volume":"7","author":"Bozza","year":"2021","journal-title":"Sci Adv"},{"issue":"suppl 1","key":"2026073011321590300_bib47","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1182\/blood-2025-4117","article-title":"In Vivo pan CAR therapy utilizing circular RNA for treatment of multiple myeloma [abstract]","volume":"146","author":"Silver","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026073011321590300_bib48","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41392-025-02512-4","article-title":"Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy","volume":"10","author":"Hu","year":"2025","journal-title":"Sig Transduct Target Ther"},{"issue":"8","key":"2026073011321590300_bib49","first-page":"102250","article-title":"Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting","volume":"6","author":"Wang","year":"2025","journal-title":"CR Med"},{"issue":"7","key":"2026073011321590300_bib50","doi-asserted-by":"crossref","first-page":"e011759","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"8","key":"2026073011321590300_bib51","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat Nanotechnol"},{"issue":"11","key":"2026073011321590300_bib52","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"suppl 3","key":"2026073011321590300_bib53","first-page":"A1712","article-title":"1482 In-vivo CAR-T cells produced by specific virus in refractory B cell lymphoma","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2026073011321590300_bib54","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1016\/j.jcyt.2025.03.432","article-title":"Lentiviral particle-mediated generation of in-vivo CAR-T cells for treating refractory B-cell lymphoma","volume":"27","author":"Chen","year":"2025","journal-title":"Cytotherapy"},{"issue":"2","key":"2026073011321590300_bib55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"2026073011321590300_bib56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026073011321590300_bib57","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2026073011321590300_bib58","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2026073011321590300_bib59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJM200301163480314","article-title":"A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency","volume":"348","author":"Hacein-Bey-Abina","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"2026073011321590300_bib60","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41375-025-02585-8","article-title":"Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy","volume":"39","author":"Ottaviano","year":"2025","journal-title":"Leukemia"},{"issue":"132","key":"2026073011321590300_bib61","doi-asserted-by":"crossref","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"issue":"1","key":"2026073011321590300_bib62","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymthe.2017.10.012","article-title":"Retroviral and lentiviral safety analysis of gene-modified T cell products and infused HIV and oncology patients","volume":"26","author":"Marcucci","year":"2018","journal-title":"Mol Ther"},{"issue":"1","key":"2026073011321590300_bib63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.2022015728","article-title":"Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs","volume":"140","author":"Steffin","year":"2022","journal-title":"Blood"},{"issue":"16","key":"2026073011321590300_bib64","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"issue":"20","key":"2026073011321590300_bib65","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"issue":"20","key":"2026073011321590300_bib66","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2026073011321590300_bib67","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"2026073011321590300_bib68","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa2309728","article-title":"CAR+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma","volume":"392","author":"Harrison","year":"2025","journal-title":"N Engl J Med"},{"key":"2026073011321590300_bib69","author":"U.S. Food and Drug Administration","year":"2024"},{"issue":"21-22","key":"2026073011321590300_bib70","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/hum.2022.090","article-title":"Regulatory consideration for the nonclinical safety assessment of gene therapies","volume":"33","author":"Moffit","year":"2022","journal-title":"Hum Gene Ther"},{"key":"2026073011321590300_bib71","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)\n          . S12: Nonclinical Biodistribution Considerations for Gene Therapy Products. ICH Harmonised Guideline, Step 4. 2023. Accessed 15 April 2026. https:\/\/database.ich.org\/sites\/default\/files\/ICH_S12_Step4_Guideline_2023_0314.pdf."},{"issue":"5","key":"2026073011321590300_bib72","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-023-00842-1","article-title":"PK\/PD and bioanalytical considerations of AAV-based gene therapies: an IQ consortium industry position paper","volume":"25","author":"Kavita","year":"2023","journal-title":"AAPS J"},{"issue":"1","key":"2026073011321590300_bib73","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat Med"},{"issue":"12","key":"2026073011321590300_bib74","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1038\/s41375-021-01324-z","article-title":"Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma","volume":"35","author":"Graham","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"2026073011321590300_bib75","doi-asserted-by":"crossref","first-page":"e010709","DOI":"10.1136\/jitc-2024-010709","article-title":"Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin\u2019s lymphoma","volume":"13","author":"Herzberg","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2026073011321590300_bib76","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymgme.2008.12.016","article-title":"Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency","volume":"96","author":"Wilson","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2026073011321590300_bib77","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2026073011321590300_bib78","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2026073011321590300_bib79","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"issue":"355","key":"2026073011321590300_bib80","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"3","key":"2026073011321590300_bib81","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41577-022-00825-x","article-title":"Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines","volume":"23","author":"Ju","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2026073011321590300_bib82","doi-asserted-by":"crossref","first-page":"e006292","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"9","key":"2026073011321590300_bib83","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026073011321590300_bib84","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41587-022-01245-x","article-title":"Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells","volume":"40","author":"Agarwalla","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"16","key":"2026073011321590300_bib85","first-page":"TPS2681","article-title":"A phase I, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed\/refractory CD19+ B-cell malignancies","volume":"43","author":"Garcia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026073011321590300_bib86","doi-asserted-by":"crossref","first-page":"e9158","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol Med"},{"key":"2026073011321590300_bib87","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.omtm.2019.03.003","article-title":"Highly efficient and selective CAR-gene transfer using CD4- and CD8-targeted lentiviral vectors","volume":"13","author":"Jamali","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"5","key":"2026073011321590300_bib88","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"2026073011321590300_bib89","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.ymthe.2025.07.006","article-title":"Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector","volume":"33","author":"Coradin","year":"2025","journal-title":"Mol Ther"},{"issue":"8","key":"2026073011321590300_bib90","doi-asserted-by":"crossref","first-page":"eabm7950","DOI":"10.1126\/sciadv.abm7950","article-title":"In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles","volume":"8","author":"Su","year":"2022","journal-title":"Sci Adv"},{"key":"2026073011321590300_bib91","doi-asserted-by":"publisher","DOI":"10.1101\/2024.10.29.620946","article-title":"Antigen-specific T cell immunotherapy by in vivo mRNA delivery","author":"Su","year":"3  2024","journal-title":"bioRxiv"},{"issue":"8110","key":"2026073011321590300_bib92","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-026-10235-x","article-title":"In vivo site-specific engineering to reprogram T cells","volume":"652","author":"Nyberg","year":"2026","journal-title":"Nature"},{"issue":"2","key":"2026073011321590300_bib93","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.immuni.2025.01.009","article-title":"In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313","volume":"58","author":"Nyberg","year":"2025","journal-title":"Immunity"}],"updated-by":[{"DOI":"10.1182\/blood.2026036165","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/5\/535\/2535811\/blood_bld-2025-031898-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/5\/535\/2535811\/blood_bld-2025-031898-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:32:42Z","timestamp":1785425562000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/5\/535\/568623\/Promises-and-potential-pitfalls-of-in-vivo-CAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031898","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,30]]},"published":{"date-parts":[[2026,7,30]]}}}